Owlet Inc OWLT is trading significantly lower Monday after the company announced it received a Warning Letter from the U.S. Food and Drug Administration.
The FDA said Owlet's marketing and functionality in the U.S. renders its Smart Sock a medical device requiring premarket clearance or approval. Owlet has not obtained clearance or approval from the FDA.
Owlet said that its Smart Sock product was evaluated in third-party studies, in which it was shown to be safe. The company plans to continue working closely with the FDA to reach a resolution.
Owlet is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident.
OWLT Price Action: Owlet was halted for volatility during Monday's trading session.
The stock was down 23.40% at $4.20 at time of publication.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
